Brendan Technologies Secures Pre-Release Purchase of STATLIA(R) Quantum with Top Ten Pharmaceutical Company
2008-08-06 07:30:00
Brendan Technologies Secures Pre-Release Purchase of STATLIA(R) Quantum with Top Ten Pharmaceutical Company
New Assay Analysis Software Demonstrates Scalability and
Flexibility
CARLSBAD, Calif.–(EMWNews)–While Brendan Technologies, Inc. (OTCBB: BDTE), an innovative analytical
software company, is completing the development of its powerful new
assay analysis software, STATLIA® Quantum, one
of the world’s top ten pharmaceutical
companies has already made an advance purchase of the system for one of
its worldwide locations. Neither the terms of the agreement nor the
company’s name was disclosed.
Brendan Technologies also has already inked a license agreement for
STATLIA Quantum with Invitrogen (NASDAQ:IVGN) to facilitate the analysis
of protein samples.
STATLIA Quantum offers “quantum leap”
advancement in assay analysis software due to its scalability,
flexibility, and industry-leading computational analysis tools. Written
in an advanced architectural design on a .NET framework, the new
software can be centrally administered throughout an organization by the
IT department. It has the flexibility to analyze multiple technologies
and applications in the laboratory, along with offering a number of
unique analysis tools made possible by its advanced and proprietary
computational capabilities.
“This purchase adds to the confirmation that
STATLIA Quantum is well positioned in the biopharmaceutical industry to
address currently unmet critical needs for assay analysis,”
said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. “The
fact that major industry players are willing to make pre-release
purchases of STATLIA Quantum underscores the need for the unique and
advanced assay analysis capabilities that this software brings to the
drug development process.”
One of the industry’s leading experts in the
field of immunoassay and bioassay testing, Dr. Dunn serves as an IBC
Life Sciences instructor teaching comprehensive training courses on the
subject of “Analyzing Biological Assays”
to the biopharmaceutical industry, and has authored several key papers
on the subject. He has been invited by the United States Pharmacopeia
(USP) regulatory agency to make a presentation at its annual USP
Bioassay Workshop held August 14 on three methods used for drug potency
testing. Brendan has incorporated all three methods under discussion in
its new STATLIA Quantum software.
About Brendan Technologies, Inc.
Brendan Technologies, a developer and marketer of innovative analytical
software, is actively providing software solutions to improve the
accuracy, quality control, workflow, and regulatory compliance of
immunoassay and bioassay testing in laboratories in the
biopharmaceutical, clinical, research, veterinarian and agricultural
industries. The Company’s customers, many of
whom are Fortune 1000 organizations, represent some of the largest
corporations in their respective fields. Brendan Technologies is
continually redesigning and expanding its product lineup to better
capitalize on the growing demand of its target markets for more advanced
software.
Background on Immunoassay Testing
Immunoassays are one of the world’s largest
and fastest growing testing technologies used to diagnose diseases,
discover new chemical entities and biological products, provide vital
data in the development of drugs in FDA clinical trials, and assist in
quality control of drug manufacturing and drug screening. It is also one
of the largest technologies used in environmental testing. Currently,
$50 billion is spent globally on immunoassay testing, with approximately
$1 billion of that being spent on immunoassay software.
Immunoassays are highly sensitive and specific chemical tests used to
detect and quantify extremely minute substances in blood, body fluid and
other biological samples, using an immunological reaction. These tests
measure the formation of antibody-antigen complexes and detect them via
an indicator reaction. Their high specificity results from the use of
antibodies and purified antigens as reagents. High sensitivity is
achieved by using an indicator system that results in amplification of
the measured product. Immunoassays may be qualitative (positive or
negative) or quantitative (amount measured).
FORWARD-LOOKING STATEMENTS: This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange
Act”), and as such, may involve risks and
uncertainties. For a discussion of such risks and uncertainties that
could cause actual results to differ from those contained in the
forward-looking statements, see “Risk Factors”
in the Company’s Annual Report on Form
10-KSB, as amended, for the most recently ended fiscal year.
Forward-looking statements, which are based on certain assumptions and
describe future plans, strategies, and expectations, are generally
identifiable by the use of words such as “believe,”
“expect,” “intend,”
“anticipate,” “estimate,”
“project,” or
similar expressions. These forward-looking statements relate to, among
other things, expectations of the business environment in which the
Company operates, projections of future performance, potential future
performance, perceived opportunities in the market, and statements
regarding the Company’s mission and vision. The Company’s
actual results, performance, and achievements may differ materially from
the results, performance, and achievements expressed or implied in such
forward-looking statements.
Brendan Technologies, Inc. 760-929-7500, Ext. 210 Investor Relations Group |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions